Steven Cohen Arcutis Biotherapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,485,425 shares of ARQT stock, worth $31 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,485,425
Previous 830,478
78.86%
Holding current value
$31 Million
Previous $13 Million
60.34%
% of portfolio
0.05%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding ARQT
# of Institutions
247Shares Held
131MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$241 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$232 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$224 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$206 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$180 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.26B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...